NAG-thiazoline, NGT, acts as mechanism based inhibitor of hexosaminidase A. In patients with Tay–Sachs disease (misfolded hexosaminidase A), NGT acts as a molecular chaperone by binding in the active site of hexosaminidase A which helps create a properly folded hexosaminidase A.
NAG-thiazoline, NGT, is a medication that inhibits hexosaminidase A's activity. In individuals with Tay–Sachs disease (where hexosaminidase A is misfolded), NGT acts as a molecular chaperone by binding to the active site of hexosaminidase A and helping it fold correctly.